Alterations in implantable cardioverter defibrillator lead parameters following left ventricular assist device implantation
- PMID: 40837543
- PMCID: PMC12362136
- DOI: 10.1016/j.jhlto.2025.100350
Alterations in implantable cardioverter defibrillator lead parameters following left ventricular assist device implantation
Abstract
Background: Left ventricular assist devices (LVADs) are increasingly used in the management of advanced heart failure. The majority of these patients have pre-existing implantable cardioverter defibrillators (ICDs). The proximity between the LVAD inflow cannula and right ventricular (RV) defibrillation lead raises the potential for disruption of ICD function.
Methods: This is a retrospective analysis of 95 patients with ICDs at a single tertiary care center who underwent LVAD implantation and who met inclusion criteria. The primary outcome was changes in the pre-operative and post-operative transvenous ICD RV lead parameters. These changes were stratified by the age of the RV lead and analyzed via a paired t-test. The secondary outcome was disruption to the ICD requiring an intervention.
Results: LVAD implantation was associated with significant decreases in sensed amplitude (p < 0.01) and high voltage impedance (p < 0.01) and an increase in capture threshold (p = 0.017). When stratified by age of the RV lead, patients with leads older than two years had similar trends in all parameters. However, RV leads that were two years old or younger only showed a significant change in high voltage impedance (p < 0.01). Mechanical disruption of the ICD related to the surgery was infrequent but significant.
Conclusion: Because LVAD implantation is capable of impacting ICD function and causing mechanical disruption, close monitoring should be paid to the ICD in the peri-operative period including obtaining a full interrogation.
Keywords: Advanced heart failure; Electrophysiology; Implantable cardioverter defibrillator (ICD); Left ventricular assist device (LVAD); Right ventricular lead disfunction.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. doi: 10.3310/hta10270. Health Technol Assess. 2006. PMID: 16904046
-
Implantable Cardioverter-Defibrillator Use in Patients With Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis.JACC Heart Fail. 2016 Oct;4(10):772-779. doi: 10.1016/j.jchf.2016.05.003. Epub 2016 Jul 6. JACC Heart Fail. 2016. PMID: 27395347
-
The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.Health Technol Assess. 2005 Nov;9(45):1-132, iii-iv. doi: 10.3310/hta9450. Health Technol Assess. 2005. PMID: 16303098
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Device-Related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-Term Follow-Up: The PRAETORIAN-XL Trial.Circulation. 2025 Jul 22;152(3):172-182. doi: 10.1161/CIRCULATIONAHA.125.074576. Epub 2025 Apr 25. Circulation. 2025. PMID: 40279654 Free PMC article. Clinical Trial.
References
LinkOut - more resources
Full Text Sources
Miscellaneous